Zeria Pharmaceutical (TOKYO:4559) (ISIN: JP3428850006) announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract. Z-338 was developed by Zeria Pharmaceutical Co., Ltd based in Tokyo, and is currently being co-developed by Astellas Pharma Inc based in Tokyo. Acotiamide is expected to be the first-in-class for FD diagnosed by the Rome Ⅲ, and will be launched in Japan ahead of the rest of the world.
The clinical trial was a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of acotiamide 100 mg three times a day for 4 weeks in patients with FD. A total of 897 FD patients from 67 medical institutions in Japan were randomized and allocated to Acotiamide group or Placebo group.
In both of two primary endpoints employed in the present study, acotiamide was statistically significantly effective when compared to placebo. Furthermore, significant improvements were observed in several secondary endpoints. The findings definitively demonstrated that acotiamide alleviated the symptoms of FD patients. No statistical difference in adverse drug reactions was noted between the Acotiamide and Placebo groups.
Based on the above results, Zeria is promptly preparing a New Drug Application for Japan jointly with Astellas Pharma. Zeria will obtain marketing authorization and manufacture acotiamide, and thereafter both companies will co-market acotiamide in Japan with a single brand name.